Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Therapeutic area crossroads: anti-angiogenesis

Nature Reviews Drug Discovery volume 7, pages 115–116 (2008)Cite this article

Lucentis versus Avastin in AMD

AMD is a degenerative disease of the retina that eventually leads to a loss of vision. An epidemiological study has recently estimated the total US prevalence of AMD at 1.75 million with significant increased prevalence rates in people aged 75 and older2. The more common wet (neovascular) form of AMD, an estimated 70% of cases2, is characterized by the abnormal growth of local choroidal blood vessels and results in a rapid loss of central vision. Because formation and growth of new blood vessels play a major role in the disease pathogenesis of wet AMD, treatment with anti-angiogenic therapies has strong scientific and clinical rationale.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Framework of product/market attributes in successive mechanism-of-action(MOA) generations.

References

  1. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273–286 (2007).

    Article  CAS  Google Scholar 

  2. The Eye Diseases Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564–572 (2004).

  3. Genentech. Lucentis US package insert. Genentech web site, [online] (2007)

  4. US Department of Health and Human Services (HHS). Your Medicare Benefits. HHS web site, [online] (2006)

  5. US National Eye Institute/National Institutes of Health (NEI/NIH). Press release: National Institutes of Health Stimulates the Development and Testing of New Therapies for Advanced Age-Related Macular Degeneration (AMD). NEI/NIH web site, [online] (2006).

  6. National Institute for Health Research (NIHR). A Randomised Controlled Trial of Alternative Treatments to Inhibit VEGF in Age-Related Choroidal Neovascularization (IVAN). NIHR web site, [online] (2007).

  7. Genentech. Commitment to Patient Access. Genentech web site, [online] (2007).

  8. Goldstein, J. & Chase M. Genentech to limit Avastin availability. The Wall Street Journal (12 Oct 2007).

    Google Scholar 

  9. American Academy of Ophthalmology (AAO). Solution to Avastin Access Found through a Joint Effort by the Academy, ASRS and Genentech. AAO web site, [online] (2007).

Download references

Author information

Authors and Affiliations

  1. Ryan P. Million is at Trinity Partners, 100 Park Avenue, Suite 1600, New York, New York 10017, USA. rmillion@trinitypartners.com,

    Ryan P. Million

Authors
  1. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

DATABASES

OMIM

Age-related macular degeneration

colon cancer

Rights and permissions

Reprints and permissions

About this article

Cite this article

Million, R. Therapeutic area crossroads: anti-angiogenesis. Nat Rev Drug Discov 7, 115–116 (2008). https://doi.org/10.1038/nrd2507

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2507

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing